chronic sinusitis News
-
Article in Journal of Magnetism and Magnetic Materials
October 10, 2016: Publication accepted by the Journal of Magnetism and Magnetic Materials on biofilm disruption with rotating micro-rods, in order to enhance efficacy of antibiotics (under image-guidance of WMP-designed systems). Biofilms have been implicated in many difficult-to-treat diseases, including chronic sinusitis and pressure ...
-
Sinusleeve™ Balloon Device Completes FDA Listing, Dalent Medical Begins Sales in South Florida
Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat Doctors is pleased to announce that the Sinusleeve™ Balloon Sinus Dilation Sleeve has completed the United States Food and Drug Administration’s listing process. The company will begin selling the Sinusleeve™ balloon device in their home state of Florida to Otolaryngologists ...
-
Dalent Medical Secures $1.5 Million Round, Granted Patent Protecting New Medical Device for ENT Physicians
Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat doctors is pleased to announce the closing of a $1.5 million funding round. The company has raised over $2 million from private investors since 2018. The additional funds will be used to produce inventory and ramp up sales & marketing to support the rollout of the company’s first patented ...
-
Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL Mini Sinus Implant
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received ...
-
Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union. The Contour CE approval expands the portfolio of PROPEL products ...
-
Creative Enzymes Introduces Chitinases for Research and Industrial Production
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with as many enzyme services and products as possible. Creative Enzymes recently announced Chitinases for research and industrial production. Chitin widely exists in the shells of crustaceans, the carapaces of insects and the cell walls of ...
-
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in ...
-
Miamitech Startup Spotlight: Dalent Aims to Improve Sinus Surgery Experience, Outcome and Cost
If you’ve ever had an awful sinus infection, you know how painful, and quite frankly, how much of a drag it is. But most of us don’t have Chronic Sinusitis, which consists of a sinus infection lasting longer than 3 months (despite treatment), according to the Mayo Clinic. That being said, 11.6% of the American population does, says the CDC. For years, if doctors couldn’t bring ...
-
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL Sinus Implant Reduces Healthcare Resource Utilization
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, ...
-
SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy
SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) today announced that it has been granted approval by Health Canada to conduct a multiCentre Phase II prevention and efficacy trial for a front-line antiviral prevention and early treatment for use against COVID-19. SaNOtize also announced that new tests conducted by the Institute for Antiviral ...
-
First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you